In recent years, molecular targeting drugs have made a breakthrough in the treatment of cancer. Some expensive targeted drugs have been included in medical insurance, and more and more cancer patients are hoping for targeted drugs.

 

However, the use of targeted drugs should be based on gene detection. We need to identify the target of gene mutation in order to achieve targeted therapeutic effect. However, the current gene detection is still a self - fee project, and the price is high, and it is much more affordable to some patients.